NY-ESO-1 antibody as a novel tumour marker of gastric cancer

S. Fujiwara, H. Wada, J. Kawada, R. Kawabata, T. Takahashi, J. Fujita, T. Hirao, K. Shibata, Y. Makari, S. Iijima, H. Nishikawa, A. A. Jungbluth, Y. Nakamura, Y. Kurokawa, M. Yamasaki, H. Miyata, K. Nakajima, S. Takiguchi, E. Nakayama, M. MoriY. Doki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.Results:NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.

Original languageEnglish
Pages (from-to)1119-1125
Number of pages7
JournalBritish journal of cancer
Volume108
Issue number5
DOIs
Publication statusPublished - Mar 19 2013
Externally publishedYes

Fingerprint

Tumor Biomarkers
Stomach Neoplasms
Antibodies
Humoral Immunity
Recurrence
Drug Therapy
Carcinoembryonic Antigen
Tumor Burden
Serum
Disease Progression
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Fujiwara, S., Wada, H., Kawada, J., Kawabata, R., Takahashi, T., Fujita, J., ... Doki, Y. (2013). NY-ESO-1 antibody as a novel tumour marker of gastric cancer. British journal of cancer, 108(5), 1119-1125. https://doi.org/10.1038/bjc.2013.51

NY-ESO-1 antibody as a novel tumour marker of gastric cancer. / Fujiwara, S.; Wada, H.; Kawada, J.; Kawabata, R.; Takahashi, T.; Fujita, J.; Hirao, T.; Shibata, K.; Makari, Y.; Iijima, S.; Nishikawa, H.; Jungbluth, A. A.; Nakamura, Y.; Kurokawa, Y.; Yamasaki, M.; Miyata, H.; Nakajima, K.; Takiguchi, S.; Nakayama, E.; Mori, M.; Doki, Y.

In: British journal of cancer, Vol. 108, No. 5, 19.03.2013, p. 1119-1125.

Research output: Contribution to journalArticle

Fujiwara, S, Wada, H, Kawada, J, Kawabata, R, Takahashi, T, Fujita, J, Hirao, T, Shibata, K, Makari, Y, Iijima, S, Nishikawa, H, Jungbluth, AA, Nakamura, Y, Kurokawa, Y, Yamasaki, M, Miyata, H, Nakajima, K, Takiguchi, S, Nakayama, E, Mori, M & Doki, Y 2013, 'NY-ESO-1 antibody as a novel tumour marker of gastric cancer', British journal of cancer, vol. 108, no. 5, pp. 1119-1125. https://doi.org/10.1038/bjc.2013.51
Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. British journal of cancer. 2013 Mar 19;108(5):1119-1125. https://doi.org/10.1038/bjc.2013.51
Fujiwara, S. ; Wada, H. ; Kawada, J. ; Kawabata, R. ; Takahashi, T. ; Fujita, J. ; Hirao, T. ; Shibata, K. ; Makari, Y. ; Iijima, S. ; Nishikawa, H. ; Jungbluth, A. A. ; Nakamura, Y. ; Kurokawa, Y. ; Yamasaki, M. ; Miyata, H. ; Nakajima, K. ; Takiguchi, S. ; Nakayama, E. ; Mori, M. ; Doki, Y. / NY-ESO-1 antibody as a novel tumour marker of gastric cancer. In: British journal of cancer. 2013 ; Vol. 108, No. 5. pp. 1119-1125.
@article{b0321268cab245a6a9b64a006312582d,
title = "NY-ESO-1 antibody as a novel tumour marker of gastric cancer",
abstract = "Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.Results:NY-ESO-1 antibodies were detected in 3.4{\%} of stage I, 4.4{\%} of stage II, 25.3{\%} of stage III, and 20.0{\%} of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2{\%} in stages III and IV, and 5.8{\%} in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.",
author = "S. Fujiwara and H. Wada and J. Kawada and R. Kawabata and T. Takahashi and J. Fujita and T. Hirao and K. Shibata and Y. Makari and S. Iijima and H. Nishikawa and Jungbluth, {A. A.} and Y. Nakamura and Y. Kurokawa and M. Yamasaki and H. Miyata and K. Nakajima and S. Takiguchi and E. Nakayama and M. Mori and Y. Doki",
year = "2013",
month = "3",
day = "19",
doi = "10.1038/bjc.2013.51",
language = "English",
volume = "108",
pages = "1119--1125",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - NY-ESO-1 antibody as a novel tumour marker of gastric cancer

AU - Fujiwara, S.

AU - Wada, H.

AU - Kawada, J.

AU - Kawabata, R.

AU - Takahashi, T.

AU - Fujita, J.

AU - Hirao, T.

AU - Shibata, K.

AU - Makari, Y.

AU - Iijima, S.

AU - Nishikawa, H.

AU - Jungbluth, A. A.

AU - Nakamura, Y.

AU - Kurokawa, Y.

AU - Yamasaki, M.

AU - Miyata, H.

AU - Nakajima, K.

AU - Takiguchi, S.

AU - Nakayama, E.

AU - Mori, M.

AU - Doki, Y.

PY - 2013/3/19

Y1 - 2013/3/19

N2 - Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.Results:NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.

AB - Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.Results:NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.

UR - http://www.scopus.com/inward/record.url?scp=84875469309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875469309&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.51

DO - 10.1038/bjc.2013.51

M3 - Article

C2 - 23403818

AN - SCOPUS:84875469309

VL - 108

SP - 1119

EP - 1125

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -